Introduction
Joint hypermobility syndrome (JHS) is an inherited disorder of the connective tissue (Grahame et al., 2000) . The common feature is pain but as this is a disorder of collagen that occurs throughout the body, it has features such as varicose veins, uterine or rectal prolapse, hernias (Bravo and Wolff, 2006) , and cardiovascular, pulmonary, gastrointestinal and gynaecological problems (Castori, 2012) . More surprising characteristics, such as disturbances in pain perception (Grahame, 2009; Mulvey et al., 2013) , anxiety (Smith et al., 2014) and fatigue (Castori et al., 2011) , have also been reported. The spectrum of physical features is broad, with some people suffering few symptoms and others with chronic long-standing joint pain, subluxations/dislocations, sprains, clumsiness and problems with activities ranging from sport to simple writing tasks (Adib et al., 2005) .
Classifying JHS is difficult because, unlike other hypermobility syndromes, there are no specific genetic tests that define the syndrome (Castori, 2012) . Furthermore, there is some confusion as JHS may be the same condition as Ehlers-Danlos syndrome (EDS) -hypermobility type (EDS-HT), formerly called EDS -Type III (Ross and Grahame, 2011) . To add to the confusion, JHS has an asymptomatic counterpart that has been termed generalized joint hypermobility (GJH). Classification is therefore important as it can guide our clinical reasoning and treatment decisions. People with JHS may require multimodal care, with consideration paid to extraarticular features and possible comorbidities.
The Beighton score (Beighton et al., 1973) is often used to assess the degree of general joint flexibility, measuring specific areas of joint hypermobility -for example, the thumbs, elbows and knees. Its reliability and validity have been demonstrated (Boyle et al., 2003; Smits-Engelsman et al., 2010) . The Beighton scoring system was originally designed by Beighton et al. (1973) as a quick tool to identify hypermobility in population studies (Foley and Bird, 2013; Remvig et al., 2011) . There are some disagreements about the cutoff score, which varies with age (Clinch et al., 2011; Lamari et al., 2005; Leone et al., 2009; Seckin et al., 2005) but commonly a score of 4 or more out of nine joints represents GJH in adults (Beighton et al., 1973) . JHS is further classified using either the Brighton criteria (Grahame et al., 2000) or the Villefranche classification (Beighton et al., 1998) . These classifications have the Beighton score embedded and also determine signs and symptoms commonly recognized as part of the syndrome. The Brighton criteria were originally designed in recognition of the extra-articular features of JHS -for example, soft-tissue rheumatism, dislocations and abnormal skin features (Grahame et al., 2000) ; however, its validity has been questioned (Remvig et al., 2011) . Currently, there are no validity or reliability studies of the Brighton criteria but good inter-examiner reproducibility has been reported by Juul-Kristensen et al. (2007) . The Villefranche classification focuses on features of inheritance and was developed to identify EDS-HT, which then helps to differentiate this from classic or vascular forms of EDS (see Appendix 1). The Brighton criteria focus on signs and symptoms, and are used to classify JHS (see Appendix 2). The Brighton criteria have two major and eight minor criteria; one of the major criterion is a score of 4 or more using the Beighton score, with the other major criterion being arthralgia for longer than three months in four or more joints. JHS is classified based on two major criteria -one major criterion and two minor criteria -or four minor criteria being fulfilled. The main differences between these two methods of classification is the Beighton cut-off level (5 or more in the Villefranche classification and 4 or more in the Brighton criteria) and skin hyper-extensibility emphasis (Scheper et al., 2015) .
GJH is seen in up to 10% of Western populations (Grahame, 1999) , with a declining prevalence with increasing age Larsson et al., 1993) and a higher prevalence among women (Larsson et al., 1993) and some ethnic groups (Seow et al., 1999) . For example, the prevalence rises to 35% of males and 57% of females in a rural Nigerian population (Birrell et al., 1994) . The prevalence of JHS is estimated to be between 0.75% and 2% (Hakim and Sahota, 2006) , but it has been reported to be as high as 45% of all people referred to rheumatologists (Grahame and Hakim, 2006) and 30% of all people referred to a British musculoskeletal triage clinic (Connelly et al., 2015) . This too can vary with ethnicity (Fikree et al., 2013) ; for example, 55% of Omani women presenting to a woman's musculoskeletal physiotherapy service had JHS (Clark and Simmonds, 2011) , and non-Caucasian women were diagnosed twice as frequently as Caucasian women in a UK general rheumatology clinic (Grahame and Hakim, 2006) .
Discussions regarding the classification of JHS are timely. Scheper et al. (2015) set out a number of challenges that relate to phenotyping JHS and its difference to GJH. This included the difficulty of clinical heterogeneity and the possibility of subtypes within the JHS spectrum. The reported prevalence of GJH and JHS within the general and musculoskeletal populations might suggest that recruitment to studies investigating differences between people with GJH and JHS would be straightforward. To understand where people with JHS are referred to within our secondary care setting and to assist with recruitment strategies for studies investigating people with JHS, we undertook a local prevalence survey. This was particularly relevant as our consultant rheumatologists' impression was that the prevalence of JHS was lower than suggested in the literature within our general rheumatology clinics. Consideration of the prevalence of JHS in various NHS clinics is key to ensuring patient satisfaction, appropriate training of clinicians, timely diagnosis (Ross and Grahame, 2011) and care pathway design as well as efficient recruitment to research programmes. With appropriate pathway design come improved clinical and cost effectiveness. Therefore, our aim was to establish the prevalence of JHS within the pain management, general rheumatology and an orthopaedic lower limb clinic in order to target our recruitment to future trials effectively. The focus upon an orthopaedic lower limb clinic was chosen as the knee is the most common site of pain (Leone et al., 2009 ).
Methods
A sample size of 101 people was calculated, based upon the assumption that the proportion of JHS within our clinics would be between 15% and 25% of the population. The first author, a senior physiotherapist with a special interest in JHS and experience of using the Brighton criteria, attended outpatient services run by the pain management, general rheumatology and orthopaedic lower limb clinics in one general hospital. Samples of convenience were taken from each of the clinics. Consecutive patients were surveyed at each of the clinics until an equal number of patients had been sampled from each of the clinical areas.
The hospital is part of a group of hospitals in North-West London, UK. Thirty clinics in total were attended between October 2013 and September 2015. As a normal part of the patients' care, the attendees were assessed for the presence of JHS using the Brighton criteria (see Appendix 2), noting the classification of
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the number of major and minor criteria. The percentage of attendees who had JHS was then recorded for each clinic.
Results
The results for 46 patients were sequentially recorded in each of the three clinics. A total of 144 patients were approached, of which 138 patients' results were assessed as four patients in the pain management and two from the general rheumatology clinics declined to be assessed for hypermobility. This represented a higher sample size than our sample size calculation suggested; this occurred as the count took place for all patients attending clinic on the surveyed days, which accounted for more people than required.
As can be seen in Fig. 1 , there was a similar prevalence of JHS in the pain management and rheumatology clinics -39.1% and 37.0%, respectively. The prevalence in the orthopaedic lower limb clinic was much lower, at 10.9%.
The percentages were further analysed by noting the Beighton score, and whether the classification was based on major or minor criteria (see Table 1 ). The percentage of people who were classified as having JHS with two major criteria in the pain management, rheumatology and orthopaedic lower limb clinics were 13.0%, 10.9% and 2.2%, respectively. The percentage of people classified with a Beighton score of 4 or more and two minor criteria were 2.2%, 0% and 2.2%, respectively. The percentage of people classified with arthralgia for longer than three months in four or more joints and two minor criteria were 21.7%, 23.9% and 4.3%, respectively. Finally, the percentage of people classified with four minor criteria was 2.2% in each group.
Discussion
More people with JHS presented to our pain management and general rheumatology clinics than the orthopaedic lower limb clinic. This reflects a more appropriate pathway for this multiple joint pathology, where orthopaedic surgery is rarely a chosen pathway of care.
Although the presence of JHS was high in the pain management and rheumatology clinics, it was similar to the percentage that others have found (Connelly et al., 2015; Grahame and Hakim, 2006) . The presence of joint hypermobility, measured as a Beighton score of 4 or more, was approximately what one might expect within the general population in the pain management and rheumatology clinics, but was far lower than expected in the orthopaedic clinic. Limiting the survey to the orthopaedic lower limb clinic rather than including orthopaedic spinal or upper limb clinics could be an influencing factor as, although the knee is thought to be a common site of pain, other areas of pain are felt by people with GJH and JHS.
If GJH occurs in approximately 10% of Western populations (Grahame, 1999) , why were our findings lower? The population demographics, particularly ethnic origin, gender and age, were not collected but local area population statistics collected in 2014 (http:// www.ibhf.gov.uk/), demonstrated that 78.1% of the population considered themselves as white and 31.9% as being from other ethnic groups. The majority of the other ethnic groups comprised Black African (5.8%), mixed (5.5%), other Asian (4%) and Black Caribbean (3.9%). This does not suggest that the percentage of GJH in the local population should be particularly low. A low Beighton score may be a result of joints stiffening with age. For example, people referred to the orthopaedic services may suffer with To et al.
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osteoarthritis and therefore represent a population with a reduced range of motion. The high percentage of people with JHS in two of the clinics was, in part, a reflection of classifying people who have a low Beighton score but have multiple joint pains from other sources. These figures may represent an over-classification in people who had co-morbidities that do not reflect a hypermobility syndrome. For example, joint pain and soft-tissue lesions are commonly associated with some immunological conditions, which may present alongside unrelated varicose veins, a hernia or a prolapse, all of which can occur in an older population. The Brighton criteria only exclude a classification of JHS in the presence of Marfan or EDS (other than EDS-HT), rather than following the exclusion of other disorders. Indeed, the Brighton criteria have only been validated against a healthy population and not yet against people with other musculoskeletal complaints (Grahame et al., 2000) . Therefore, the sensitivity and specificity of the criteria require further investigation. Remvig et al. (2011) suggested that further investigations should include the determination of features that may contribute towards heterogeneity of JHS. This stresses the need for the Brighton criteria to be considered alongside a thorough history taking, consideration of other differential diagnoses, and careful clinical reasoning to avoid the risk of over-classification. For example, a shoulder dislocation that is traumatic in origin could re-dislocate owing to a Hill-Sachs lesion but fulfil a minor criterion. A careful history needs to be taken to avoid attributing such an unrelated dislocation to JHS. This may also be the case for myopia, a hernia from a traumatic football injury, or a prolapse sustained by a mother during traumatic childbirth. Sub-classifications of JHS have been demonstrated in children (Pacey et al., 2015) and adults (De Wandele et al., 2013) . The identification of these subtypes was based on symptoms such as fatigue, gastrointestinal problems and postural orthostatic tachycardia syndrome. It should be noted that these features [fatigue (Castori et al., 2011; , gastrointestinal problems (Fikree et al., 2013) and postural orthostatic tachycardia syndrome (Mathias et al., 2012) ], although associated (Castori, 2012) , are not, as yet, considered part of the classification criteria.
In conclusion, recruitment to trials using the Brighton criteria to achieve an accurate diagnosis of JHS rather than general hypermobility is challenging. Sensitivity and specificity testing of the Brighton criteria against other populations is required because this cohort of people who have widespread pain and symptoms requires accurate identification. It is crucial to ensure that people are directed to appropriate specialist services within secondary care, to receive an early diagnosis. Identifying and diagnosing the relevant condition aids appropriate and effective care pathways. This is important as it can have a significant effect on their functional ability and quality of life. A high prevalence of JHS within some clinics should put clinicians on alert to seek out whether joint hypermobility is a relevant factor for their patients. COL5A1, collagen type 5 alpha 1; COL5A2, collagen type 5 alpha 2; COL3A1, collagen type 3 alpha 1; PLOD1, procollagen-lysine, 2-oxoglutarate 5-dioxygenase; COL1A1, collagen type 1 alpha 1; ADAMTS2, A disintegrin-like and metalloproteinase with thrombospondin type 1 motif, 2
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